Novo Nordisk (NVO) plans to start a late-stage clinical program next year to test oral and injectable forms of its new ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

Novo Nordisk and Deep Apple Therapeutics Inc. have entered a research collaboration and exclusive license agreement.

Denmark's Novo Nordisk is partnering with biotech company Deep Apple Therapeutics in a deal worth up to $812 million to ...

Novo Nordisk will pay U.S. biotech Deep Apple Therapeutics up to $812 million in a partnership deal aimed at developing drugs to treat cardiometabolic diseases, including obesity.

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

SNY, BMY, REGN and others ramp up 2025 dealmaking as pharma/biotech giants chase innovation across key growth areas.

Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the ...

The PD-(L)1xVEGF field had a roller coaster week marked by an imperfect readout and a potentially $11 billion deal. | The PD- ...

REGN inks a $2B-plus obesity drug deal with Hansoh, aiming to expand its pipeline amid slumping Eylea sales and pipeline ...

The deal, which could be worth up to $870 million overall, will give Lilly access to a delivery technology that may help ...

Regeneron licensed a weight loss drug and revealed study data for a pair of muscle-preserving medicines. Elsewhere, two neuroscience biotechs cut deals and Bluebird officially went private.